Business Wire

Source Photonics and Credo Semiconductor Demonstrate Single Lambda 100G Connectivity Over 20km of Fiber With Compact TOSA and ROSA Assemblies

Jaa

ECOC -- Source Photonics and Credo Semiconductor are pleased to announce a single lambda 100Gbits/sec connectivity demonstration over 20km of fiber using a compact TOSA and ROSA capable of 53Gbaud PAM4 operation.

Increasing demand for more bandwidth in Cloud Data Centers is creating the need for more efficient and higher throughput optical transceivers beyond the currently deployed 100G 4x25G WDM technology. These next generation transceivers will need to support higher order modulation techniques such as PAM4 and higher data rate operation at 53Gbaud. Implementations that can be supported with this technology include 400G-DR4/FR4 in addition to 100G-DR/FR/LR.

The demonstration consists of Source Photonics internally packaged TOSA and ROSA sub-assemblies in an optical loopback configuration through 20km of single-mode fiber using a single 100G channel of Credo’s low power PAM4 IC technology. The bit-error-rate (BER) after 20km of fiber remained better than the KP4 FEC requirement and was around 5x10-5. The TOSA is based on Source Photonics’ EML laser technology which provides the necessary bandwidth to achieve a TDECQ value below 2.5dB. The room temperature link budget of 10dB provides considerable margin for the most significant link specifications under development in the industry, allowing production margin for performance variations. These results show that the building blocks necessary to realize 53Gbaud single lambda operation are available and ready to serve the needs of next generation data center deployments.

What this demonstration achieves with one laser and one receiver currently requires four lasers and four receivers – facilitating not only lower cost future 100G but also accelerating the development of 400G products.

“We are continuing to invest in next generation technology, such as Single Lambda 100G, as part of our commitment to providing leading edge solutions for data centers,” said Manish Mehta, EVP, PLM Source Photonics.

“The HyperScale Cloud Providers have spoken and 100G per lambda solutions are a key connectivity priority,” said Rajan Pai, Vice President of System Applications at Credo. “Our unique SerDes architecture allows us to deliver single-lane 100G performance at the lowest power which will enable the volume deployments of 100G and 400G optical modules.”

Source Photonics will be hosting a private demonstration at their booth number 162 at ECOC 2017 to be held in Gothenburg, Sweden from September 18-20, 2017. To schedule an appointment to view the demo, please contact Jasmin Basal at jasmin.basa@sourcephotonics.com.

About Source Photonics

Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in data centers, metro, and access networks. We invent next-generation solutions to provide customers with enabling technologies to support the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises worldwide. Source Photonics is headquartered in West Hills, California, with manufacturing facilities, R&D, and sales offices worldwide. For more information about Source Photonics, please visit www.sourcephotonics.com.

About Credo Semiconductor

Credo is a leading provider of high performance, mixed-signal semiconductor solutions for the data center, enterprise networking and high performance computing markets. Credo's advanced Serializer-Deserializer (SerDes) technology delivers the bandwidth scalability and end-to-end signal integrity for next generation platforms requiring single-lane 25G, 50G, and 100G connectivity. The company makes its SerDes available in the form of Intellectual Property (IP) licensing on the most advanced processing nodes and with complementary product families focused on extending reach and multiplexing to higher data rates. Credo is headquartered in Milpitas, California and has offices in Shanghai and Hong Kong. For more information: www.credosemi.com

Contact information

Source Photonics
Jasmin Basal, 818-885-4202
Marketing Communications
jasmin.basa@sourcephotonics.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Beko Becomes the Naming Partner of Fenerbahçe Men's Basketball Team19.12.2018 13:00Tiedote

To forge its support to sports and healthy living, Beko is now the naming partner of Fenerbahçe Men's Basketball Team. Beko has been supporting basketball teams in Turkish Basketball League and also sponsored the European Basketball Championship for many years and now it takes on the naming partnership of Fenerbahçe Men's Basketball Team for 2.5 years. This new naming partnership agreement focuses on “Eat Like A Pro” – an initiative launched by Beko to fight childhood obesity. Through this collaboration, Beko plans to expand the scope of the campaign to promote healthy eating habits among children by advertising their hero basketball players as role models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005026/en/ Beko Becomes Naming Partner of Fenerbahce Men’s Basketball Team (Photo: Business Wire) Beko, a leading white goods brand providing products and services in more than 130 countries, returns to investing in bas

Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 11:00Tiedote

The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease

Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil

SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 10:50Tiedote

SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING

Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 10:39Tiedote

Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme